Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Current Assets (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed Current Assets for 17 consecutive years, with $29.4 billion as the latest value for Q4 2025.

  • Quarterly Current Assets fell 1.31% to $29.4 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $29.4 billion through Dec 2025, down 1.31% year-over-year, with the annual reading at $29.4 billion for FY2025, 1.31% down from the prior year.
  • Current Assets for Q4 2025 was $29.4 billion at Bristol Myers Squibb, down from $35.6 billion in the prior quarter.
  • The five-year high for Current Assets was $35.6 billion in Q3 2025, with the low at $26.8 billion in Q3 2022.
  • Average Current Assets over 5 years is $29.6 billion, with a median of $29.3 billion recorded in 2021.
  • The sharpest move saw Current Assets fell 18.01% in 2022, then grew 26.91% in 2025.
  • Over 5 years, Current Assets stood at $33.3 billion in 2021, then fell by 18.01% to $27.3 billion in 2022, then increased by 16.49% to $31.8 billion in 2023, then fell by 6.26% to $29.8 billion in 2024, then decreased by 1.31% to $29.4 billion in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $29.4 billion, $35.6 billion, and $33.2 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.